Last reviewed · How we verify

Naropin 0.1% cum sufentanil

Bent Gymoese Jorgensen · Phase 3 active Small molecule

Naropin 0.1% cum sufentanil is a Local anesthetic with opioid analgesic combination Small molecule drug developed by Bent Gymoese Jorgensen. It is currently in Phase 3 development for Regional anesthesia and analgesia (epidural or peripheral nerve block), Postoperative pain management. Also known as: Local analgetic, Ropivacain.

Naropin (ropivacaine) is a local anesthetic that blocks sodium channels in nerve membranes, while sufentanil is an opioid agonist that enhances analgesia through mu-receptor activation.

Naropin (ropivacaine) is a local anesthetic that blocks sodium channels in nerve membranes, while sufentanil is an opioid agonist that enhances analgesia through mu-receptor activation. Used for Regional anesthesia and analgesia (epidural or peripheral nerve block), Postoperative pain management.

At a glance

Generic nameNaropin 0.1% cum sufentanil
Also known asLocal analgetic, Ropivacain
SponsorBent Gymoese Jorgensen
Drug classLocal anesthetic with opioid analgesic combination
TargetVoltage-gated sodium channels (ropivacaine); mu-opioid receptor (sufentanil)
ModalitySmall molecule
Therapeutic areaAnesthesia, Pain Management
PhasePhase 3

Mechanism of action

Ropivacaine reversibly inhibits sodium influx in nerve fibers, preventing depolarization and action potential propagation, thereby producing local anesthesia. Sufentanil, a potent synthetic opioid, binds to mu-opioid receptors in the central and peripheral nervous system to provide additional analgesia and enhance the overall pain-relieving effect of the combination.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Naropin 0.1% cum sufentanil

What is Naropin 0.1% cum sufentanil?

Naropin 0.1% cum sufentanil is a Local anesthetic with opioid analgesic combination drug developed by Bent Gymoese Jorgensen, indicated for Regional anesthesia and analgesia (epidural or peripheral nerve block), Postoperative pain management.

How does Naropin 0.1% cum sufentanil work?

Naropin (ropivacaine) is a local anesthetic that blocks sodium channels in nerve membranes, while sufentanil is an opioid agonist that enhances analgesia through mu-receptor activation.

What is Naropin 0.1% cum sufentanil used for?

Naropin 0.1% cum sufentanil is indicated for Regional anesthesia and analgesia (epidural or peripheral nerve block), Postoperative pain management.

Who makes Naropin 0.1% cum sufentanil?

Naropin 0.1% cum sufentanil is developed by Bent Gymoese Jorgensen (see full Bent Gymoese Jorgensen pipeline at /company/bent-gymoese-jorgensen).

Is Naropin 0.1% cum sufentanil also known as anything else?

Naropin 0.1% cum sufentanil is also known as Local analgetic, Ropivacain.

What drug class is Naropin 0.1% cum sufentanil in?

Naropin 0.1% cum sufentanil belongs to the Local anesthetic with opioid analgesic combination class. See all Local anesthetic with opioid analgesic combination drugs at /class/local-anesthetic-with-opioid-analgesic-combination.

What development phase is Naropin 0.1% cum sufentanil in?

Naropin 0.1% cum sufentanil is in Phase 3.

What are the side effects of Naropin 0.1% cum sufentanil?

Common side effects of Naropin 0.1% cum sufentanil include Hypotension, Bradycardia, Nausea, Dizziness, Respiratory depression, Pruritus.

What does Naropin 0.1% cum sufentanil target?

Naropin 0.1% cum sufentanil targets Voltage-gated sodium channels (ropivacaine); mu-opioid receptor (sufentanil) and is a Local anesthetic with opioid analgesic combination.

Related